Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 11/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | HPGDS | O60760 | 3/20 | 0.37 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30714614 | 0.88 | GUCY1B2 (0.40) | SLC6A5CHRNA7 | |
| SCHEMBL30714585 | 0.87 | SLC6A5 (0.42) | SLC6A5CHRNA7 | |
| SCHEMBL30714717 | 0.85 | HTR3A (0.47) | SLC6A5HPGDS | |
| SCHEMBL30714613 | 0.84 | CD38 (0.40) | SLC6A5MAPK1HPGDSHRH2HRH1 | |
| SCHEMBL24485587 | 0.83 | LMNA (0.40) | SLC6A5MAPK1HPGDS | |
| SCHEMBL30714616 | 0.83 | NPC1 (0.40) | HPGDS | |
| SCHEMBL30714561 | 0.81 | HPGDS (0.38) | SLC6A5MAPK1HPGDSHRH2HRH1 | |
| SCHEMBL26868539 | 0.81 | NMT2 (0.38) | HPGDS | |
| SCHEMBL31539873 | 0.80 | SLC8A1 (0.34) | MAPK1 | |
| SCHEMBL30714593 | 0.79 | MMP12 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-12-11 | — | — | US | disclosed |
| EP-4499624-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023230540-A2 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376461-A1 | INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | TRPV3, TRPM2, TRPV1 | SLC6A5 904/4885MAPK1 2209/4885HPGDS 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.